Prostate Cancer Daily

October 24, 2024

Videos

Peer-to-Peer Clinical Conversations

Prostate Cancer QuickTakes ESMO 2024 - ARANOTE, PEACE-3, and SPLASH Trials - Oliver Sartor

Oliver Sartor

Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024.

STEAP1-Targeted T-Cell Engager Demonstrates Efficacy in mCRPC Patients - William Kevin Kelly

William Kelly

Oliver Sartor interviews William Kevin Kelly about findings on AMG 509 (Xaluritamig), a STEAP1-targeted T-cell engager for advanced prostate cancer.

Beyond the Abstracts

Combining PSMA-PET and PROMISE to Re-Define Disease Stage and Risk in Patients with Prostate Cancer: A Multicentre Retrospective Study - Beyond the Abstract

De-Escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium - Beyond the Abstract

Conference Coverage

ESMO 2024: Targeting Epigenetic Pathways

ESMO 2024: Invited Discussant: CC-94676-PCA-001 and INSPIRE

ESMO 2024: Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer: An Ancillary Study of the PEACE-1 Phase 3 Trial

ESMO 2024: Invited Discussant: Efficacy of SPLASH and UpFrontPSMA Trials

ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor (SPLASH)

Physician-Scientist Review Articles

ESMO 2024 Quick Take Insights: A Focus on ARANOTE

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Optimizing prostate cancer detection in transition zone: an analysis of apparent diffusion coefficient values in prostate magnetic resonance imaging evaluation with Prostate Imaging Reporting and Data System (PI-RADS) assessment.

Should Military Veterans Be Classified as High Risk for Prostate Cancer Screening? A Systematic Review and Meta-analysis.

Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.

Clinical Factors Associated with Suspicious 18F-DCFPyL PSMA PET Activity in Patients Initially Managed with Radical Prostatectomy including PSA <0.5 ng/mL.

The homeodomain regulates stable DNA binding of prostate cancer target ONECUT2.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC